Abstract:Background: Ischemic stroke is an acute cerebrovascular disease with high mortality rates and poor prognoses. The influence of ischemic stroke includes a heavy economic burden to patients and society, making the exploration of new therapeutic targets for preventing and treating ischemic stroke urgent. This study aimed to explore the effect of phosphoglycerate mutase family member 5 (PGAM5) on oxidative stress and mitochondrial dysfunction in ischemic stroke. Methods: The model of ischemic neuronal brain injury was established through culturing purchased human neuroblastoma cells (SH-SY5Y) by oxygen-glucose deprivation/reoxygenation (OGD/R). There were six experimental groups, including the OGD/R model group (SH-cells of OGD/R model), OE-NC group (cells of OGD/R model transfected with scramble cDNA), OE-PGAM5 group (cells of OGD/R model transfected with full-length sequence of PGAM5), si-NC group (cells of OGD/R model transfected with negative control small interference (si)RNA), si-PGAM5 group (cells of OGD/R model transfected with siRNA for PGAM5 knockdown), and a control group (cells cultured normally). Cell counting kit-8 (CCK-8) and flow cytometry were used to determine the activity and apoptosis of cells. Subsequently, the effects of PGAM5 expression on oxidative stress and mitochondrial dysfunction were analyzed. Mitochondrial morphology was observed by transmission electron microscopy (TEM), and mitochondrial membrane potential (MMP) was determined by JC-1 fluorescent probe. The levels of reactive oxygen species (ROS) were measured by flow cytometry, and levels of malondialdehyde (MDA) and superoxide dismutase (SOD) were measured by enzyme-linked immunosorbent assay (ELISA) assay. The expression of light chain (LC)3-II/I and autophagy-related gene 5 (ATG5) proteins were measured, and the regulation of PGAM5 expression on PTEN-induced putative protein kinase 1 (PINK1)/Parkin pathway was also explored. Results: PGAM5 overexpression in OGD/R cells decreased the cell viability (p < 0.001) while increasing cell apoptosis (p < 0.01) compared to the OGD/R group. Inhibition of PGAM5 expression reversed the decreased cell viability (p < 0.001) and the increased cell apoptosis (p < 0.01). The JC-1 fluorescence showed that OGD/R treatment reduced mitochondrial membrane potential (p < 0.001) and TEM showed an obvious increase in phagosomes. In addition, OGD/R treatment enhanced oxidative stress (increased ROS, p < 0.01; increased MDA, p < 0.001; decreased SOD, p < 0.001), which could be further enhanced by overexpression of PGAM5 (ROS, p < 0.001; MDA, p < 0.001; SOD, p < 0.001) while reversed by the inhibition of PGAM5 (ROS, p < 0.01; MDA, p < 0.001; SOD, p < 0.001). The OGD/R-activated PINK1/Parkin pathway was inhibited by the knockdown of PGAM5 (p < 0.01) but promoted by the overexpression of PGAM5 (p < 0.05). Conclusions: PGAM5 stimulates oxidative stress and impairs mitochondrial function in ischemic stroke, and regulates the PINK1/Parkin signaling pathway. Therefore, PGAM5 is likely to be a target for the therapy of ischemic stroke.

CDK5 Inhibition Protects Against OGDR Induced Mitochondrial Fragmentation and Apoptosis Through Regulation of Drp1S616 Phosphorylation.

Cdk1 Protects Against Oxygen-Glucose Deprivation and Reperfusion-Induced Golgi Fragmentation and Apoptosis Through Mediating GM130 Phosphorylation.

Neuroprotective Mechanisms Mediated by CDK5 Inhibition.

Parkin Protects Against Oxygen-Glucose Deprivation/Reperfusion Insult by Promoting Drp1 Degradation

The Role of Cdk5‐mediated Drp1 Phosphorylation in Aβ1‐42 Induced Mitochondrial Fission and Neuronal Apoptosis

The Inhibition of Cdk5 Activity after Hypoxia/ischemia Injury Reduces Infarct Size and Promotes Functional Recovery in Neonatal Rats.

The Involvement of Programmed Cell Death 5 (pdcd5) in the Regulation of Apoptosis in Cerebral Ischemia/Reperfusion Injury

Role of CDK5 in Neuroprotection from Serum Deprivation by Μ-Opioid Receptor Agonist

Protective effects of PIK3CG knockdown against OGD/R-induced neuronal damage via inhibition of autophagy through the AMPK/mTOR pathway

The Peptide-Directed Lysosomal Degradation of CDK5 Exerts Therapeutic Effects Against Stroke

Cdk5-Mediated Drp1 Phosphorylation Drives Mitochondrial Defects and Neuronal Apoptosis in Radiation-Induced Optic Neuropathy

Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury After Traumatic Brain Injury Through Drp1-Mediated Mitochondrial Dysfunction

Inhibition of Drp1 ameliorates diabetic retinopathy by regulating mitochondrial homeostasis

Dynamin- Related Protein 1 Inhibitors Protect Against Ischemic Toxicity Through Attenuating Mitochondrial Ca2+ Uptake From Endoplasmic Reticulum Store In Pc12 Cells

DRD4 Mitigates Myocardial Ischemia/Reperfusion Injury in Association With PI3K/AKT Mediated Glucose Metabolism

Recovery of Neurovascular Unit Integrity by CDK5-KD Astrocyte Transplantation in a Global Cerebral Ischemia Model

Inhibition of ERK downregulates autophagy via mitigating mitochondrial fragmentation to protect SH-SY5Y cells from OGD/R injury

CDK5 knockdown in astrocytes provide neuroprotection as a trophic source via Rac1

Abstract WP261: Dcr1 and Dcr2 Protect Neuron Against Ischemia and Hypoxia Damage Via Differential Mechanisms on Ischemia Preconditioning-Induced Neuroprotection

Abstract 3774: The effect of CDK5 on mitochondrial function in Glioblastoma Multiforme (GBM)

The Effect of PGAM5 on Regulating Mitochondrial Dysfunction in Ischemic Stroke